Your session is about to expire
← Back to Search
Combination Therapy for Prostate Cancer
Study Summary
This trial is testing a new way to treat high risk prostate cancer that may be more effective than current methods.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of lung conditions like interstitial lung disease or pulmonary fibrosis.I have had surgery to remove my prostate.My prostate cancer diagnosis was confirmed through a biopsy.I have been treated with a PD-1 or PD-L1 inhibitor before.I haven't had any other cancer besides non-melanoma skin cancer or in situ carcinoma, or if I did, it was over 2 years ago and fully treated.I am fully active or can carry out light work.My prostate cancer is high risk with a Gleason score of 8+, 3+ bone metastases, or visceral metastasis.I have brain metastases confirmed by tests.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I do not have an active infection like TB, hepatitis B, or C.I have been treated with specific prostate cancer medications for over 8 weeks.I can understand and am willing to sign the consent form myself or have someone legally authorized to do so on my behalf.My heart functions well despite a history of heart issues, with an ejection fraction over 40%.I have wounds, ulcers, or bone fractures that are healing slowly.I do not have HIV/AIDS or I am not on antiretroviral therapy.I have or had an autoimmune or inflammatory disorder like Crohn's disease or lupus.I have not received a live vaccine in the last 4 weeks.I am allergic to certain chemotherapy drugs or hormone therapy medications.My blood counts and kidney and liver functions are within normal ranges.I am a man who meets the trial's criteria.I haven't been on hormone therapy for prostate cancer for more than 12 weeks.I am a man who meets the trial's criteria, regardless of my race or ethnicity.I have been diagnosed with prostate cancer through a biopsy.I haven't taken immunosuppressive drugs in the last 14 days, with some exceptions.
- Group 1: First Strike then Second Strike
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What studies have been conducted using Luteinizing Hormone Releasing Hormone as an intervention?
"Presently, 643 trials are investigating the effects of Luteinizing Hormone Releasing Hormone. 209 of those clinical studies are Phase 3 and are concentrated in Germantown, Tennessee; however, there exist 38,624 locations that offer this treatment option."
How many participants are enrolled in this trial to its fullest extent?
"Affirmative. According to the information available on clinicaltrials.gov, this medical trial is currently recruiting patients - it was initially posted on January 25th 2022 and its most recent update came through November 28th 2022. It seeks 31 participants from a single medical centre."
To what afflictions is Luteinizing Hormone Releasing Hormone typically administered?
"Luteinizing Hormone Releasing Hormone is usually employed to combat malignant neoplasms, yet its efficacy can also be observed in therapeutic procedures, hypogonadotropic ovarian failure and sarcoma."
What is the federal regulatory stance on Luteinizing Hormone Releasing Hormone?
"Our team at Power rated Luteinizing Hormone Releasing Hormone with a score of 2. This is due to the medication being in Phase 2, meaning that it has some safety data but there are no efficacy studies yet conducted."
Are there any vacancies for participants in this trial?
"Affirmative, the information archived on clinicaltrials.gov suggests that this experiment is currently enlisting volunteers. The trial was inaugurated on January 25th 2022 and its most recent update occurred November 28th 2022 - with a total of 31 participants being sought from one site."
Share this study with friends
Copy Link
Messenger